Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyre...
Q2 2026
Jul 30, 2026
Q1 2026
Apr 30, 2026
FY 2025
Feb 12, 2026
Q4 2025
Q3 2025
Oct 30, 2025
